on INNATE PHARMA (EPA:IPH)
Innate Pharma to Present at Jefferies Global Healthcare Conference
Marseille-based Innate Pharma SA has announced its participation in the Jefferies Global Healthcare Conference 2025. The presentation is scheduled for November 17, 2025, from 2:30 to 2:55 PM GMT in London. Innate Pharma's executive team will engage in one-on-one meetings to discuss their current projects and advancements in immunotherapy for cancer treatment. A live webcast will be accessible through Innate Pharma's website.
Innate Pharma is known for developing antibody therapeutics focused on unmet medical needs. Their portfolio includes IPH4502, an ADC for solid tumors, lacutamab for T cell lymphomas, and monalizumab, developed with AstraZeneca for lung cancer. The company collaborates with major firms like Sanofi and AstraZeneca, emphasizing innovation in immuno-oncology.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INNATE PHARMA news